New drug duo aims to tame rare bone marrow cancer
NCT ID NCT03564873
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 24 times
Summary
This study tests a combination of two drugs, omacetaxine and azacitidine, in people with a high-grade form of myelodysplastic syndromes (MDS), a bone marrow disorder. The goal is to find the safest dose and see how many patients achieve remission. About 28 adults with newly diagnosed high-grade MDS will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Universtiy of Colorado Denver
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.